Enanta Pharmaceuticals

Enanta Pharmaceuticals

生物技术研究

Watertown,MA 9,810 位关注者

Our vision is to transform the lives of patients with curative therapies.

关于我们

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET? (U.S.) and MAVIRET? (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

网站
https://www.enanta.com
所属行业
生物技术研究
规模
51-200 人
总部
Watertown,MA
类型
上市公司
领域
Virology和Immunology

地点

Enanta Pharmaceuticals员工

动态

相似主页

查看职位

融资